Prevention of preparation errors of cytotoxic drugs in centralized units: From epidemiology to quality assurance;Maîtrise des erreurs de préparation des médicaments anticancéreux en unité centralisée: De l'é pidémiologie à l'assurance qualité

Bulletin du Cancer

Volumn 91, Issue 12, 2004, Pages 972-976

  Martin, Frédéric ^a   Legat, Christine ^a   Coutet, Jérôme ^a   Bracco Nolin, Claire Hélène ^a   Jacquet, Micheline ^a   Woronoff Lemsi, Marie Christine ^a   Limat, Samuel ^a,b  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b UFR Pharmacie   (France)

Author keywords

Cytotoxic drug; Medication error; Preparation error; Quality assurance

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT;

ARTICLE; DRUG FORMULATION; HEALTH CARE POLICY; MEDICATION ERROR; PHARMACY; QUALITY CONTROL; RISK FACTOR; RISK MANAGEMENT;

ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; DRUG COMPOUNDING; MEDICATION ERRORS; PHARMACY SERVICE, HOSPITAL; QUALITY CONTROL;

EID: 12844284475     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Gallelli J. Issues and risks associated with handling antineoplasic drugs. J Pharm Pract 1991; 4: 72-6.
2. Valanis B, Vollmer W, Labuhn K, Glass A. Association of ancineoplasic drug handling with acute adverse effects in pharmacy personnel. Am J Hosp Pharm 1993; 50: 455-62.
3. Power LA, Anderson RW, Cortopassi R, Gera JR, Lewis RM. Update of safe handling of hazardous drugs: the advice of experts. Am J Hosp Pharm 1990; 47: 1050-60.
4. DeMeo M, Merono S, DeBaille AD, Botta A, Laget M, Guiraud H, et al. Monitoring exposure of hospital personnel handling cytotoxic drugs and contaminated materials. Int Arch Occup Environ Health 1995; 66: 363-8.
5. Sessink PJ, Wittenhorst B, Anzion RB, Bos RP. Exposure of pharmacy technicians to antineoplasic agents: reevaluation after additional protective measures. Arch Environ Health 1997; 52: 240-4.
6. Sessink PJ, Boer KA, Scheefhals AP, Anzion RB, Bos RP. Occupational exposure to antineoplasic at several department in a hospital. Environmental contamination and excretion of cyclophospamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health 1992; 64: 105-12.
7. Pethran A, Schierl R, Hauff K, Grimm CH, Boos KS, Nowak D. Uptake of antineoplasic agents in pharmacy and hospital personnel. Part I: monitoring of urinary concentrations. Int Arch Occup Environ Health 2003; 76: 5-10.
8. Ziegler E, Mason H, Baxter PJ. Occupational exposure to cytotoxic drugs in two UK oncology wards. Occup Environ Med 2002; 59: 608-12.
9. Augry F, Iltis A, Letellier D. Evaluation de l'économie réalisée au sein d'une unité centralisée de fabrication des médicaments cytotoxiques destinées à la voie parentérale. J Pharm Clin 1996; 15: 12-4.
10. Favier M, Fliche E, Bressolle F. Economic benefit of a centralized reconstitution unit of cytotoxic drug in isolator. J Oncol Pharm Pract 1996; 2: 182-5.
11. Légat C, Limat S, Coutet J, D'Attoma F, Jacquet M, Woronoff-Lemsi MC. Impact économique de la préparation centralisée des médicaments anticancéreux. J Pharm Clin 2003; 22: 181-5.
12. American Society Hospital Pharmacy. ASHP guidelines on quality assurance for pharmacy prepared sterile produces. Am J Health Syst Pharm 2000; 57: 1150-69.
13. Favier M, Hansel S, Bressolle F. Preparing cytotoxic agents in an isolator. Am J Hosp Pharm 1993; 50: 2335-9.
14. Tillet L. Barrier isolators as an alternative to a cleanroom. Am J Health Syst Pharm 1999; 56: 1433-6.
15. Pelus E, Dellanegra M, Charlety D, Magnin N, Petit N, Meylan I. Unité de préparation centralisée des cytotoxiques: de la mise en place à l'assurance qualité. J Pharm Clin 1998; 17: 97-102.
16. Augry R, Ravaud P, Lopez I, Letellier D, Iltis A, Bouscary D, et al. Erreurs de prescription des médicaments cytotoxiques: étude prospective de 5000 ordonnances. J Pharm Clin 1998; 17: 20-4.
17. Van Der Bemt PM, Egberts T, De Jong-Van Der Berg L, Brouwers J. Drug-relared problems in hospitalised patients. Drug Saf 2000; 22: 321-33.
18. Fernandez C. Can we prevent cytotoxic disasters? Br J Haematol 2000; 108: 464-9.
19. Limat S, Madroszyk-Flandin A, Nallet G, Dessard-Choupay G, Jacquet M, Woronoff-Lemsi MC. Risque iatrogène lié à la prescription des médicaments anticancéreux. Oncologie 2002; 4: 203-8.
20. Ritter H, Trissel L, Anderson R, Moyer L, Morales J. Electronic balance as quality assurance for cyrotoxic drug admixtures. Am J Health Syst Pharm 1996; 53: 2318-20.
21. Basuyau F, Brunelle P. Comparaison de deux mesures physiques rapides pour le contrôle de la dose des préparations injectables de médicaments anticancéreux avant administration: application au 5-fluorouracile. J Pharm Clin 2000; 19: 5-8.
22. Flynn E, Pearson R, Barker K. Observational study of accuracy in compounding i.v. admixtures at five hospitals. Am J Health Syst Pharm 1997; 54: 904-12.
23. Escoms M, Cabanas M, Oliveras M, Hidalgo E, Barroso C. Errors evolution and analysis in antineoplasic drug preparation during one year. Pharm World Sci 1996; 18: 178-81.
24. Limat S, Drouhin JP, Demesmay K, Tissot E, Jacquet M, Woronoff-Lemsi MC. Incidence and risk factors of preparation errors in a centralized cytotoxic preparation unit. Pharm World Sci 2001; 23: 102-6.
25. Quach V, Hernando V, Combeau D, Brion F. Control evaluation of cytotoxic infusion preparations in isolator. Proc Eur Assos Hosp Pharm 2000; 24; abstract 55.
26. Bordet F, Crauste-Manciet S, Brossard D. Analyse des préparations non-conformes d'une unité de préparation des cytotoxiques. Proc Hopipharm 2000; 61; abstract 69.
27. Cauchetier E, Fernandes E, Sedrati N, Avril J, Corbri V. Evaluation d'un système qualité en pharmacotechnie. Proc SNPHPU 2000; abstract 06.
28. Bourget P, Paci A, Rey JB, Mercier L, Demirdjian S. Contribution of high-performance thin-layer chromatography to a pharmaceutical quality assurance programme in a hospital chemotherapy manufacturing unit. Eur J Pharm Biopharm 2003; 56: 445-51.
29. André V, Oudoul D, Jacques V. Validation des procédé s de fabrication en vue de la mise en place d'une unité de reconstitution des cytotoxiques. Proc SNPHPU 2001; abstract 22.
30. Giroux F, Marie Dit Dinard B, Javaudin L. Contrôle qualitatif et quantitatif des préparations de cisplatine et vinotelbine par spectrométrie UV. Proc SNPHPU 2001; Abstract 10.